Whois & Analysis for trelegy.com

Fluticasone furoate/vilanterol (FF/VI), sold under the trade names Breo Ellipta and Relvar Ellipta, is a combination medication for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β2 agonist (ultra-LABA).

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst and Flonase Sensimist (US), Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, and South Korea) for the treatment of allergic rhinitis administered by a nasal spray.

Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term poor airflow.

The main symptoms include shortness of breath and cough with sputum production.

COPD is a progressive disease, meaning it typically worsens over time.

Eventually everyday activities, such as walking up stairs, become difficult.

Chronic bronchitis and emphysema are older terms used for different types of COPD.

The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.

An inhaler (or puffer) is a medical device used for delivering medication into the body via the lungs.

It is mainly used in the treatment of asthma and chronic obstructive pulmonary disease.

Zanamivir, used to treat influenza, must be administered via inhaler.